BRCA1/2 Flu Vaccine

Last updated: November 4, 2024
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

Seasonal influenza vaccine

Clinical Study ID

NCT04499534
UPCC 11119
834194
  • Ages > 25
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to determine whether immune function in healthy individuals with germline loss of function BRCA1/2 mutations, impacts overall immune health and fitness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Males and females

  • Over age 25

  • BRCA1 or BRCA2 pathogenic or likely pathogenic mutation

  • No personal cancer history apart from non melanoma skin cancer, localized thyroidcancer, in situ cancers of any type

  • Participants must sign the informed consent form

Exclusion

Exclusion Criteria:

  • Are allergic to influenza vaccination

  • Have received influenza vaccination within the past 6 months

  • Require prednisone, methotrexate, or other immunosuppressing medications

  • Have HIV infection

  • Have a history of solid organ tumor or bone marrow transplant

  • Require combination immunotherapy;

  • Are on other studies requiring blood draws that might exceed 450 mL total during theperiod of the influenza vaccine study

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Seasonal influenza vaccine
Phase:
Study Start date:
October 28, 2019
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.